Industry S Science News
U.S. midterm election results brighten prospects for science
Research advocates welcome Democrats taking Congress but must still deal with Trump
The latest biotech and pharma news from the trade press, updated every hour and linked straight to the publisher. Follow funding, clinical, deals and more. Every story links straight to its publisher.
Industry S Science News
Research advocates welcome Democrats taking Congress but must still deal with Trump
Industry S Science News
Ancient DNA sheds light on history of modern languages such as Welsh and Gaelic
Software S Science News
Science investigation reveals firms have amassed tens of millions of hours of brain wave data from neurotech headbands, and face few constraints in using it
Funding
BioCentury
BIOCENTURY | MANAGEMENT TRACKSWITH VIDYA ACQUISITION, GUJRATHI TAKES CHAIR ROLE AT PROCESSAPlus: Orbis hires Smith-Farrell as CEO after Be Bio goes dark; and more
Industry S Science News
As prospectors struggle, a new French borehole hints at potential of extracting gas from groundwater
Clinical
Fierce Pharma
Rethinking Alzheimer's Trial Recruitment Discover how Alzheimer’s trial recruitment is evolving as research moves earlier in the disease. Explore strategies for engaging patients, caregivers and at-risk family members, reducing recruitment barriers, improving trial design and bui…
Clinical
Fierce Biotech
Rethinking Alzheimer's Trial Recruitment Discover how Alzheimer’s trial recruitment is evolving as research moves earlier in the disease. Explore strategies for engaging patients, caregivers and at-risk family members, reducing recruitment barriers, improving trial design and bui…
Industry
BioCentury
BIOCENTURY | EMERGING COMPANY PROFILECASPIAN: REGENERATING BETA CELLS WITH A MENIN INHIBITORKura Oncology spinout raised $50M to test whether an oral menin inhibitor can regrow patients’ own insulin-producing cells
Regulatory
BioCentury
BIOCENTURY | EDITOR'S COMMENTARYFDA NEEDS A ROADMAP FOR DISEASE-AGNOSTIC DRUG DEVELOPMENT — A PERSPECTIVESuppressor tRNAs show why developers need clarity on the evidence required to support approval across genes and rare diseases
Research N Nature Medicine
Clinical N Nature Medicine
Regulatory
Nature Reviews Drug Discovery
Industry
Nature Reviews Drug Discovery
Industry N Nature Medicine
Industry N Nature Reviews Bioengineering
Funding
BioCentury
BIOCENTURY | DATA BYTERADIOPHARMA VENTURE MONEY MOVES TOWARD ALPHA EMITTERSAc-225 and Pb-212 dominate this year’s funding, with one large round accounting for much of the total
Industry
MedCity News
Flagship Pioneering unveiled Etcelera, a new startup formed by combining three of the firm’s portfolio companies. Etcelera’s approach to drug R&D focuses on “causal intelligence,” which Flagship defines as predicting and understanding cause and effect in biology. The post Fla…
Manufacturing
C&EN Pharmaceuticals
The deal will double Lonza’s US footprint and boost its capability in bioconjugates
Research
GEN
Nightingale Health will run the measurements in its labs using Alamar’s NULISA platform to quantify hundreds of blood proteins in 80,000 UK Biobank samples, seeking early molecular signs of neurodegeneration. The post Alamar, Nightingale Health Team up on UK Biobank Neurodegenera…
Industry S SecureBio
Moonshot’s newest model performs comparably to Kimi K3 on our biology capabilities evaluations, maintaining the gap behind closed-weight models.
Industry
STAT Biotech
Servier reports a surprise setback for a drug being tested for a form of muscular dystrophy that lacks treatment.
Clinical A Applied Clinical Trials
Neuroscience trials struggle to show benefit because symptoms are subjective and variable, and eCOA strengthens dossiers by standardizing ClinRO administration, capturing outcomes in real time to reduce recall bias, and adding patient and caregiver perspectives that clinician sca…
Agriculture
CropLife
New research funded by the [foundationfar.org]Foundation for Food & Agriculture Research’s (FFAR) Growing Impact Award could help plant breeders and farmers respond more rapidly to food production needs. FFAR and matching funders Iowa State University (ISU), KeyGene, KWS and…
Industry
GEN
In this GEN podcast, a cellular workflow automation specialist from Molecular Devices explores what precision automation means for working biologists and how purpose-built instruments, software, and expertise can support it. The conversation covers where variability creeps into c…
Agriculture
CropLife
Eligible parts are now backed by 24 months or 4,000 machine hours of coverage, helping customers manage maintenance and repair costs with greater confidence and choice. The post John Deere Announces an Industry-Leading Eligible Parts Warranty, Delivering More Value and Choice to…
Industry
Inside Precision Medicine
A new experimental approach to treating lupus targets an abnormality in how immune cells respond to the hormone prolactin. The strategy reduced harmful immune activity and prevented kidney damage in mice while largely preserving healthy immune cells, raising hopes for more select…
Manufacturing B BioPharm International
Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
Agriculture
CropLife
Grant is part of USDA-NRCS’s $65 million investment in new conservation tools, practices, and technologies on private lands. The post Field to Market Awarded USDA-NRCS Conservation Innovation Grant to Bring Field-Level Water Quality Estimates to Farmers appeared first on CropLife…
Manufacturing B BioPharm International
Today’s BioPharm Brief covers FDA’s final potency assurance guidance for cell and gene therapies, Lonza’s deal to acquire Merck KGaA’s US CDMO business, and Phase 2a data for Tiziana’s intranasal anti-CD3 antibody foralumab in progressive multiple sclerosis.
Software
Fierce Pharma
Digital Twins: Advancing Clinical Evidence Strategy pesurya Tue, 11/03/2026 - 14:04
Research A Applied Clinical Trials
Community participation gaps look less like a question of patient willingness and more like a financing and infrastructure problem that no single bill has yet solved.
Industry
Fierce Pharma
Creators and Influencers in Life Sciences: A New Force in Paid Media Join CMI Media Group’s Julie Hurvitz Aliaga, EVP, Innovation, Content & Partnerships, and Kyrus Keenan Westcott, health advocate and creator of The Vibe with Ky, for a discussion on how creator partnerships…
Industry
Inside Precision Medicine
In vivo gene editing has successfully treated a patient with alpha-1 antitrypsin deficiency, a condition affecting the liver and lungs. The post Base-Editing Gene Therapy Successfully Targets Inherited Disorder appeared first on Inside Precision Medicine.
Clinical
GEN
Following 12 weeks of treatment, Recursion said, 87% of patients (13 of 15) had a reduction in total polyp burden, with a 47% median reduction. Approximately one in three patients achieved reductions of ≥65%. The post Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After…
Funding P Pharmaceutical Executive
Lonza will add bioconjugate, payload-linker and viral vector capacity and about 1,100 employees; closing is expected in mid-2027.
Industry B BioPharm International
At AAPS PharmSci 360 2026, University of Iowa PhD candidate Siddhanth Hejmady explains how adding a payload or radiolabel to trastuzumab changes its behavior in bulk solution and at interfaces, and why developability teams should pair DLS with QCM-D.
Manufacturing
C&EN Pharmaceuticals
Here’s what we’re watching in the chemical and pharmaceutical industries this week
Regulatory
BioPharma Dive
On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.
Software T The Niche
I check the FDA warning letters database about twice a month for new biologics warnings. The FDA posts new letters weekly. Sometimes weeks or months go by with no new warnings from the CBER branch. 2026 has brought a steady stream of cell therapy-related warnings. Two notable, ne…
Regulatory
MedTech Dive
Patients, providers and medtech firms submitted hundreds of comments to the Food and Drug Administration on how the agency should approach generative AI in medical devices.